Publications by authors named "Anjan K Nayak"

Rice production faces a significant threat from the rice leaffolder, . To address this challenge, growing resistant varieties stands out as a sustainable and eco-friendly pest management strategy. This necessitates identifying resistant sources and understanding their inheritance patterns through employing DNA markers for marker-assisted resistance breeding.

View Article and Find Full Text PDF
Article Synopsis
  • - Compound 1 effectively inhibits the TGF-β receptor type-1 but lacks metabolic stability, making it less viable for use.
  • - Researchers modified a part of this compound to improve its stability and enhance its effectiveness in cells and in mice.
  • - The study details the structure-activity relationship (SAR) that resulted in the identification of MDV6058 (PF-06952229) as a promising candidate for further preclinical development.
View Article and Find Full Text PDF

Although new targeted therapies, such as ibrutinib and idelalisib, have made a large impact on non-Hodgkin's lymphoma (NHL) patients, the disease is often fatal because patients are initially resistant to these targeted therapies, or because they eventually develop resistance. New drugs and treatments are necessary for these patients. One attractive approach is to inhibit multiple parallel pathways that drive the growth of these hematologic tumors, possibly prolonging the duration of the response and reducing resistance.

View Article and Find Full Text PDF
Article Synopsis
  • Aberrant B-cell activation is linked to various cancers and blood disorders, making them a target for treatment.
  • BTK and PI3Kδ are important kinases involved in B-cell signaling, and their inhibitors have shown promise in treating specific lymphomas.
  • The study introduces new compounds that effectively inhibit both BTK and PI3Kδ, potentially enhancing treatment responses and addressing resistance in B-cell diseases.
View Article and Find Full Text PDF

While enzalutamide and abiraterone are approved for treatment of metastatic castration-resistant prostate cancer (mCRPC), approximately 20-40% of patients have no response to these agents. It has been stipulated that the lack of response and the development of secondary resistance to these drugs may be due to the presence of AR splice variants. HDAC6 has a role in regulating the androgen receptor (AR) by modulating heat shock protein 90 (Hsp90) acetylation, which controls the nuclear localization and activation of the AR in androgen-dependent and independent scenarios.

View Article and Find Full Text PDF